Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Auro Pharmacies, Inc.
483
•Auro Pharmacies, Inc.•November 5, 2015

Auro Pharmacies, Inc. – FDA 483, Nov 5, 2015

Record Details

The FDA Form 483 details numerous deficiencies at a firm manufacturing sterile drug products. Key issues include a lack of endotoxin testing for released products (e.g., Ascorbic Acid, Glutathione) and sublots, and unvalidated endotoxin test methods. Sterility test methods were inadequate, lacking suitability determination for products like Ascorbic Acid and Glutathione, and an insufficient number of containers were tested.

Process simulations were deficient, with no growth promotion for media, and simulations were not conducted for lyophilization or the preparation of vials and stoppers. Lyophilization processes for HCG Injection and Glutathione Lyophilize were not validated.

Aseptic processing practices were compromised by operator behavior, including touching surfaces without sanitizing gloves and leaning into the laminar flow hood. Environmental monitoring was inconsistent, with a gap in viable air monitoring and no established alert/action limits for personnel monitoring. Personnel monitoring was not performed after each operational shift.

The firm lacked documented investigations for out-of-specification endotoxin results and quality-related events (e.g., suspected high endotoxin levels, patient reactions). Stability testing programs were absent for products like Ascorbic Acid 500mg/ml Injection, and ongoing stability programs were not in place to ensure potency and sterility throughout the 6-month shelf life. Preservative effectiveness determination was not conducted for products containing preservatives, and preservative concentration was not assayed. The firm also lacked data to support the storage duration

Company
Auro Pharmacies, Inc.
Inspection date
November 5, 2015
Product type
Drugs
Office
Los Angeles District Office
Person
  • Uttaniti Limchumroon
View Company Profile

ID · 6bf486ed-2c82-4c2a-b2dd-14801cfc37d7

Violation Codes10
21 CFR 211.113(b)21 CFR 211.100(a)21 CFR 211.160(b)FD&C Act 801(a)(3)FD&C Act 501(a)(2)(B)21 CFR 211.166(b)21 CFR 211.165(a)21 CFR 210.1(b)21 CFR 211.167(a)21 CFR 211.42(c)(10)(v)

Full citation text and observation details available on the Dashboard.

Other documents for Auro Pharmacies, Inc.
  • 483 - 2022-08-12August 12, 2022
  • 483 - 2018-08-02August 2, 2018
  • WARNING_LETTER - 2015-11-05November 5, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Auro Pharmacies, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.